Consensus ADMA Biologics, Inc.

Stocks

ADMA

US0008991046

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-11-02 EST			5-day change	1st Jan Change
11.06 ^USD	-3.07%		+3.56%	-39.36%

08-05	ADMA Biologics, Inc., Q2 2026 Earnings Call, Aug 05, 2026
08-05	Tranche Update on ADMA Biologics, Inc.'s Equity Buyback Plan announced on May 7, 2025.	CI

Evolution of the Average Target: ADMA Biologics, Inc.

Evolution of the Target Price: ADMA Biologics, Inc.

Changes in Analyst Recommendations: ADMA Biologics, Inc.

b4a.whWmZbBESLWjp7ZguaOc_ht30UDS28KcP_Ny-IZ2pJo.qVDTK_NwffT8yPsT7sL5yXlH5HeI6_fuVp0mst5BndH0Qc4MwQkD6tfx1Q~678cb18e2c0c3885e4638c881391e95c

Analysts' recommendations: ADMA Biologics, Inc.

04-21	Canaccord Genuity Initiates Coverage on ADMA Biologics With Buy Rating, $21 Price Target	MT
03-26	ADMA Biologics Shares Fall After Downgrade From Cantor Fitzgerald	MT
03-26	Cantor Fitzgerald Downgrades ADMA Biologics to Neutral From Overweight	MT
03-24	Culper Research says we are short ADMA Biologics	RE
25-08-06	ADMA Biologics Q2 revenue rises on increased ASCENIV utilization	RE
24-07-09	Cantor Fitzgerald Adjusts Price Target on ADMA Biologics to $15 From $10, Maintains Overweight Rating	MT
24-06-20	Mizuho Securities Raises Price Target on ADMA Biologics to $14 From $12, Maintains Buy Rating	MT
24-05-10	HC Wainwright Adjusts ADMA Biologics' Price Target to $10 From $7.50, Maintains Buy Rating	MT
24-05-10	Cantor Fitzgerald Adjusts ADMA Biologics' Price Target to $10 From $8, Maintains Overweight Rating	MT
24-03-26	HC Wainwright Adjusts ADMA Biologics Price Target to $7.50 From $6, Maintains Buy Rating	MT
24-03-01	Mizuho Adjusts Price Target on ADMA Biologics to $10 From $9, Maintains Buy Rating	MT
24-01-22	Mizuho Securities Raises Price Target on ADMA Biologics to $9 From $7, Maintains Buy Rating	MT
24-01-09	HC Wainwright Adjusts Price Target on ADMA Biologics to $6 From $5, Maintains Buy Rating	MT
23-08-10	Raymond James Adjusts Price Target on ADMA Biologics to $6 From $5, Maintains Strong Buy Rating	MT
23-08-10	HC Wainwright Adjusts Price Target on ADMA Biologics to $5 From $4.50, Maintains Buy Rating	MT
23-01-03	HC Wainwright Ups Price Target on ADMA Biologics to $4.50 From $4, Keeps Buy Rating	MT
22-11-10	Mizuho Securities Adjusts Price Target on ADMA Biologics to $6 From $5, Maintains Buy Rating	MT
22-10-13	Mizuho Securities Starts ADMA Biologics at Buy With $5 Price Target	MT
22-07-25	HC Wainwright Adjusts ADMA Biologics' Price Target to $4 from $6, Keeps Buy Rating	MT
21-11-11	Raymond James Upgrades ADMA Biologics to Strong Buy From Outperform; Keeps Price Target at $5	MT
21-11-09	Cantor Fitzgerald Starts ADMA Biologics at Overweight With $4.50 Price Target	MT
21-08-02	ADMA Biologics : Chardan Suspends Coverage on ADMA Biologics at Buy Rating With $11 Price Target	MT
21-07-06	ADMA Biologics : HC Wainwright Adjusts ADMA Biologics' Price Target to $7 From $10, Keeps Buy Rating	MT
21-03-26	ADMA Biologics : Raymond James Adjusts ADMA Biologics' Price Target to $6 From $7, Maintains Outperform Rating	MT
21-01-04	ADMA Biologics : HC Wainwright Adjusts ADMA Biologics' Price Target to $11 From $12, Keeps at Buy	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ADMA BIOLOGICS, INC.					+48.99%
	ELI LILLY AND COMPANY					+0.25%
	JOHNSON & JOHNSON					+2.27%
	ABBVIE INC.					+0.77%
	ROCHE HOLDING AG					-2.72%
	MERCK & CO., INC.					+6.95%
	NOVARTIS AG					-5.37%
	ASTRAZENECA PLC					+12.86%
	AMGEN INC.					-14.74%
	GILEAD SCIENCES, INC.					+1.07%
	Average					+5.03%
	Weighted average by Cap.					+0.57%